Enterprise Value
-139.8M
Cash
501.5M
Avg Qtr Burn
N/A
Short % of Float
6.29%
Insider Ownership
3.97%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HETLIOZ® (tasimelteon) Details SMS (Smith-Magenis Syndrome) | Approved Quarterly sales | |
Fanapt® (iloperidone) Details Schizophrenia and PDP (Parkinson's disease psychosis) | Approved Quarterly sales | |
HETLIOZ® (tasimelteon) Details Non-24-Hour Sleep-Wake Disorder (Non-24) | Approved Quarterly sales | |
Fanapt® (iloperidone) Details Mental health, Bipolar depression, Bipolar disease | sNDA Submission | |
Tradipitant Details Gastroparesis | NDA Submission | |
HETLIOZ® (tasimelteon) Details Jet Lag Disorder | NDA FDA meeting | |
Tradipitant Details Pruritus in Atopic Dermatitis | EPIONE | Phase 3 Update | |
Tradipitant Details Motion sickness | Phase 3 Update | |
VQW-765 (Alpha-7 nicotinic acetylcholine receptor
partial agonist) Details Social Anxiety Disorder | Phase 2 Data readout | |
Trichostatin A (VTR-297) Details Leukemia, Multiple myeloma, Lymphoma | Phase 1 Update | |
Failed Discontinued |